Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Cornea-Cutting Laser Cleared for Cataract Surgery
Apr 2013
ORLANDO, Fla., April 4, 2013 — Lensar Inc.’s cornea-cutting laser has received 510(k) FDA clearance for cataract surgery, the company announced Thursday.

The Lensar Laser System is cleared to perform corneal and arcuate incisions, which are done on the periphery of the cornea during surgery, as well as lens fragmentation and anterior capsulotomy (with or without phacofragmentation) during cataract surgery.

“Until recently, these small and challenging incisions in the cornea were made manually, leading to variability in predictable outcomes,” said Dr. Louis “Skip” Nichamin, a member of Lensar’s medical advisory board. “Lensar’s advanced technology platform will help cataract surgeons achieve consistent, predictable arcuate incision outcomes, regardless of the challenges and complexity of the procedure.”

The device provides physicians with an advanced platform for conducting bladeless cataract surgery and achieving consistent, predictable outcomes. The platform features next-generation differentiating Augmented Reality technology consisting of proprietary high-resolution imaging and measurement technology that provides precise biometric information and 3-D reconstruction of the anterior anatomy of the eye.

The system, which easily adapts to existing surgical facilities, is available in the US, Europe and several other countries.

For more information, visit:

510(k) FDA clearanceAmericasBiophotonicsBusinesscataract surgerycornea cutting laserDr. Louis NichaminFloridaindustriallasersLensar Inc.Lensar Laser SystemNick Curtis

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.